P1697: CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB
Irina Murakhovskaya,
Concetta Crivera,
Ann Leon,
Evo Alemao,
Vamshi Ruthwik Anupindi,
Mitch Dekoven,
Victoria Divino,
Iris Lin,
Cathye Shu,
Tarek Ebrahim
Affiliations
Irina Murakhovskaya
1 Albert Einstein College of Medicine/Montefiore Medical Center, Department of Hematology and Oncology, Bronx, NY, United States
Concetta Crivera
2 Janssen Global Services, LLC, Horsham, PA, United States
Ann Leon
3 Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA,, United States
Evo Alemao
2 Janssen Global Services, LLC, Horsham, PA, United States
Vamshi Ruthwik Anupindi
4 IQVIA Inc, Falls Church, United States
Mitch Dekoven
4 IQVIA Inc, Falls Church, United States
Victoria Divino
4 IQVIA Inc, Falls Church, United States
Iris Lin
5 Janssen Scientific Affairs, LLC, Horsham, PA, United States
Cathye Shu
6 Janssen Research & Development, LLC, Spring House, PA, USA, United States
Tarek Ebrahim
7 Janssen Pharmaceutical Companies of Johnson & Johnson, Cambridge, MA, United States
